Zydus Cadila has received the tentative approval from the USFDA to market Sitagliptin and Metformin Hydrochloride Extended-Release Tablets, (US RLD - JANUMET® XR), 50 mg/500 mg, 50 mg/ 1,000 mg and 100 mg/ 1,000 mg. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.
It contains two oral antidiabetic medications used in the management of type 2 diabetes - Sitagliptin and metformin hydrochloride extended-release.
The group now has 255 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.331.5 as compared to the previous close of Rs. 336.35. The total number of shares traded during the day was 62973 in over 886 trades.
The stock hit an intraday high of Rs. 337.7 and intraday low of 327.65. The net turnover during the day was Rs. 20931079.